VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
OCGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
OCGNOcugen, Inc.
$0.74$251M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksOCGNFinancials

Ocugen, Inc. (OCGN) Income Statement

14Y historyFree accessUpdated daily

Revenue has advanced only from $1.0M in 2024Q1 to $1.5M in 2026Q2 with COGS recorded at $0, leaving the reported 100% gross margin uninformative while operating losses widened to -$16.4M and the 2026Q2 net loss reached -$24.9M on roughly $8.5M of below-the-line charges.

Income StatementBalance SheetCash FlowRatios

OCGN Income Statement

Annual statement

OCGN Income Statement

Ocugen, Inc. (OCGN) annual income statement — 14-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Sales/Revenue4.78M4.41M4.05M6.04M2.49M043K0000008K26K
Revenue Growth %-11.01%8.83%-32.82%142.6%--100%-------100%-69.23%-
Cost of Goods Sold548K2.39M1.97M704K006.35M8.09M49.62K1.53M1.67M1.61M000
COGS % of Revenue-54.14%48.53%11.66%--14776.74%--------
Gross Profit4.23M2.02M2.09M5.33M2.49M0-6.31M-8.09M-49.62K-1.53M-1.67M-1.61M08K26K
Gross Margin %88.53%45.86%51.47%88.34%100%--14676.74%------100%100%
Gross Profit Growth %--3.02%-60.86%114.31%-100%21.95%-16194.86%96.77%8.31%-3.66%--100%-69.23%-
Operating Expenses73.26M64.94M56.84M70.86M91.56M58.03M14.97M6.08M25.84M24.95M30.11M31.51M32.6M16.79M14.99M
OpEx % of Revenue-1471.56%1401.82%1174.01%3680.02%-34823.26%------209912.5%57669.23%
Selling, General & Admin28.7M27.58M26.69M31.99M35.4M22.92M7.97M6.08M10.2M9.38M8.53M8.27M6.75M4.85M3.05M
SG&A % of Revenue-624.95%658.1%530.05%1422.83%-18544.19%------60587.5%11742.31%
Research & Development45.12M39.75M32.13M39.57M56.16M35.11M13.35M8.09M15.63M15.57M21.58M23.24M25.86M11.95M11.94M
R&D % of Revenue-900.75%792.26%655.62%2257.19%-31055.81%------149325%45926.92%
Other Operating Expenses-548K-2.39M-1.97M-704K00-6.35M-8.09M0-116K-248K-72K13K-52K-30K
Operating Income-69.03M-62.92M-54.76M-65.53M-89.07M-58.03M-21.29M-14.16M-30.11M-24.95M-30.31M-31.82M-32.66M-16.84M-14.97M
Operating Margin %-1444.47%-1425.7%-1350.36%-1085.67%-3580.02%--49500%-------210562.5%-57569.23%
Operating Income Growth %--14.9%16.44%26.43%-53.5%-172.62%-50.29%52.96%-20.67%17.68%4.75%2.58%-93.9%-12.54%-
EBITDA-66.71M-60.53M-52.79M-64.83M-88.59M-57.8M-21.18M-14.1M-30.06M-23.42M-28.63M-30.2M-31.94M-16.28M-14.33M
EBITDA Margin %-1395.89%-1371.56%-1301.82%-1074.01%-3560.73%--49262.79%-------203487.5%-55115.38%
EBITDA Growth %-18.33%-14.66%18.57%26.82%-53.27%-172.86%-50.21%53.08%-28.37%18.22%5.2%5.42%-96.18%-13.6%-
D&A (Non-Cash Add-back)2.32M2.39M1.97M704K480K229K102K61K49.62K1.53M1.67M1.61M726K566K638K
EBIT-71.86M-62.66M-54.05M-63.08M-86.8M-58.34M-14.29M-14.16M-14.47M-26.41M-13.05M-31.89M-22.64M-16.79M-14.97M
Net Interest Income-9.55M-4.27M1.3M2.5M1.4M-79K-719.9K-1.77M000000-798K
Interest Income1.32M922K1.3M2.5M1.4M01.06K1.21K0000000
Interest Expense10.22M5.19M00079K720.96K1.77M163K134K-60K-133K-151K0798K
Other Income/Expense3.67M-4.93M703K2.45M2.27M-389K-537K-6.08M11.89M-1.46M14.1M-205K9.87M-8.87M-1.97M
Pretax Income-65.36M-67.85M-54.05M-63.08M-86.8M-58.42M-21.82M-20.24M-8.64M-26.41M-16.21M-32.02M-22.79M-25.71M-16.93M
Pretax Margin %-1367.61%-1537.41%-1333.02%-1045.03%-3488.91%--50748.84%-------321400%-65134.62%
Income Tax00000-52K00-15.76M-186K00000
Effective Tax Rate %0%0%0%0%0%0.09%0%0%182.36%0.7%0%0%0%0%0%
Net Income-65.36M-67.85M-54.05M-63.08M-86.8M-58.37M-21.82M-20.24M-8.64M-26.41M-16.21M-32.02M-22.79M-25.71M-16.93M
Net Margin %-1367.61%-1537.41%-1333.02%-1045.03%-3488.91%--50748.84%-------321400%-65134.62%
Net Income Growth %-2.09%-25.52%14.31%27.33%-48.73%-167.46%-7.8%-134.21%67.28%-62.97%49.39%-40.5%11.35%-51.83%-
Net Income (Continuing)-65.36M-67.85M-54.05M-63.08M-86.8M-58.37M-21.82M-20.24M-18.22M-26.41M-16.21M-32.02M-22.79M-25.71M-16.93M
Discontinued Operations000000000000000
Minority Interest000000000000000
EPS (Diluted)-0.19-0.23-0.20-0.26-0.40-0.30-0.31-1.53-13.98-69.91-67.58-145.22-891.47-120.93-79.65
EPS Growth %9.09%-15%23.08%35%-33.33%3.23%79.74%89.06%80%-3.45%53.46%83.71%-637.18%-51.83%-
EPS (Basic)--0.23-0.20-0.26-0.40-0.30-0.31-1.53-13.98-69.91-68.21-145.22-891.47-120.93-79.65
Diluted Shares Outstanding339.21M300.17M271M244.33M214.6M195.01M112.24M13.89M618.18K377.84K239.82K220.52K25.57K212.62K212.62K
Basic Shares Outstanding339.21M300.17M271M244.33M214.6M195.01M112.24M13.89M618.18K377.83K237.62K220.52K25.57K212.62K212.62K
Dividend Payout Ratio---------------

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

R&D Outpacing Revenue Growth

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Flat Revenue Amid Volatile Quarters

As reported in Ocugen's quarterly statements, revenue has moved only from $1.0M in 2024Q1 to $1.5M in 2026Q2, a roughly 50% gain spread over ten quarters with swings as wide as -125.3% and +135.3% quarter-over-quarter.

The last three quarters ($1.8M, -$193K, $1.5M) suggest recognition is lumpy rather than tied to a growing commercial base, so the headline growth rates appear to measure timing, not demand. Because COGS is recorded at zero, there is no volume-versus-price decomposition available; revenue adds almost nothing to a cost base near $18M per quarter. Investors should treat the 8.4% and 3.5% recent growth prints as noise around a flat top line until a durable revenue driver is evidenced.

Zero-COGS Model Distorts Margin Read

According to Ocugen's reported figures, gross margin has printed 100.0% in every quarter because COGS is recorded at $0, leaving gross profit equal to revenue and rendering the metric uninformative about pricing power or manufacturing efficiency.

At $1.5M, gross profit covers only about 8% of the $17.9M in combined R&D and SG&A for 2026Q2, so the structural issue is scale, not margin compression. Peer comparables such as BEAM at 84.0% and NTLA at 76.5% achieve similar margin optics on 27x-93x Ocugen's revenue, underscoring that Ocugen's 100% figure reflects an absence of commercial activity rather than competitive positioning. The 2025Q4 line showing -$193K gross profit alongside a 100.0% margin and a positive 88.1% operating margin is internally inconsistent and warrants further investigation.

Losses Deepen Despite Overhead Triage

As disclosed in Ocugen's income statements, the operating loss widened from -$12.2M in 2024Q1 to -$16.4M in 2026Q2 as operating expenses climbed from $13.2M to $17.9M, while revenue contributed only $1.5M of offset, roughly 12 times the top line.

There is no observable operating leverage because incremental gross profit is immaterial; each additional dollar of R&D or SG&A falls straight through to operating income. SG&A has oscillated between $6.1M and $8.2M without a clear trend, which may indicate project-timed or collaboration-linked spending rather than a controlled overhead trajectory. The operating margin deteriorated from -12.0% to -11.1% over the period only because revenue ticked up slightly, not because costs were absorbed.

Below-Line Items Inflate Q2 Loss

In 2026Q2, Ocugen's net loss of -$24.9M exceeded its -$16.4M operating loss by roughly $8.5M, the widest gap in the ten-quarter series, implying non-operating charges that warrant further investigation before treating the -$0.07 quarterly EPS as a run-rate.

Stock-based compensation of $1.8M-$3.4M per quarter is a recurring non-cash drag that appears to be growing faster than revenue, peaking at $3.4M in 2026Q1 against $1.5M of sales. Dilution is already visible in the EPS path, which moved from -$0.04 in 2024Q2 to -$0.07 in 2026Q2 even as quarterly losses expanded, so per-share deterioration outpaces the absolute loss growth on certain periods. Tax and other non-operating detail is not disclosed in the supplied data, limiting how far the quality of the -$19.2M and -$24.9M net prints can be decomposed.

What Could Invalidate the Base Case

A short-seller would note that Ocugen's -$24.9M quarterly net loss is more than 16 times its $1.5M revenue while R&D has advanced to $10.7M without any corresponding revenue inflection, suggesting the cost base may be outrunning any visible return.

R&D stepped up from $6.8M in 2024Q1 to $11.3M in 2026Q1, a 66% increase that produced no durable uplift in the revenue line, which questions whether program spending is converting into monetizable milestones. The widening gap between operating loss and net loss, plus rising SBC, hints that reported results may be increasingly influenced by items outside core operations, an area a bear would probe first. Cash runway and balance-sheet capacity are not provided in the supplied data, so the ability to fund this trajectory remains unverified and is the key variable investors should monitor.

OCGN — Frequently Asked Questions

Quick answers to the most common questions about buying OCGN stock.

What was Ocugen, Inc.'s (OCGN) revenue in 2025?

For fiscal year 2025, Ocugen, Inc. (OCGN) reported total revenue of $4.4M. This represents a 16873.1% increase compared to $0.0M in 2012.

Is Ocugen, Inc. (OCGN) profitable?

Ocugen, Inc. (OCGN) reported a net loss of $67.8M for the fiscal year ending 2025.

What is Ocugen, Inc.'s operating profit margin?

Ocugen, Inc. (OCGN) reported an operating income of $-62.9M, resulting in an operating profit margin of -1425.7%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Ocugen, Inc.'s gross profit and gross margin?

Ocugen, Inc. (OCGN) generated $2.0M in gross profit for the year, representing a gross profit margin of 45.9%. This demonstrates the company's core pricing power and production efficiency.